Evidence map›Paper›PMID 40740241›Full record

ArticleJournal of Cancer2025

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.

Martin Svaton, Magdalena Knetki-Wroblewska, Petr Hosek, Gabriela Chowaniecova, Jan Spacek, Ondrej Fischer, Ondrej Bilek, Michal Hrnciarik, Diego Kauffmann-Guerrero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martin SvatonDepartment of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
Magdalena Knetki-WroblewskaDepartment of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland.
Petr HosekLaboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine Pilsen, Charles University, Pilsen, Czech Republic.
Gabriela ChowaniecovaDepartment of Clinical Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovakia.
Jan SpacekDepartment of oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Ondrej FischerDepartment of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Ondrej BilekDepartment of Oncology, Masaryk Institute of Oncology, Brno, Czech Republic.
Michal HrnciarikPulmonary Department, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Diego Kauffmann-GuerreroDepartment of Medicine V, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemotherapyhigh PD-L1 expressionimmunochemotherapy, pembrolizumabNSCLCreal-world evidence

Identifiers

PMID40740241
PMCPMC12305429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.